Overview


According to FutureWise analysis the market for Angiotensin Converting Enzyme (ACE) Inhibitors in 2023 is US$ 3.63 billion, and is expected to reach US$ 5.42 billion by 2031 at a CAGR of 5.10%.

Angiotensin Converting Enzyme (ACE) inhibitors are the medication that helps relax the veins and arteries to lower blood pressure. Angiotensin-converting enzyme inhibitors act by inhibiting an enzyme in the body responsible for the production of angiotensin II, a substance that causes the narrowing of blood vessels. This narrowing can lead to elevated blood pressure, placing additional strain on the heart. Angiotensin II is a hormone circulating in the bloodstream, exerting various effects on the cardiovascular system, primarily causing the constriction of blood vessels. Such contraction can result in high blood pressure and increased workload for the heart, especially if it has been weakened due to a heart attack or heart failure. ACE inhibitors exhibit the production of angiotensin II, effectively preventing the constriction of blood vessels. This action leads to a reduction in blood pressure and decreases the amount of energy the heart needs to exert with each heartbeat.

Initially, ACE inhibitors were primarily utilized to reduce high blood pressure (hypertension) by relaxing constricted blood vessels. However, with numerous other effective agents to lower blood pressure, new opportunities emerged for therapy with ACE inhibitors. Specifically, individuals with weakened heart muscles, leading to heart failure, exhibited elevated levels of angiotensin II in their blood. Recognizing this, using ACE inhibitors in such patients proved highly beneficial. It was established that administering ACE inhibitors to individuals with heart failure delayed the onset of symptoms, prevented heart failure-related deaths, and reduced the frequency of hospitalizations. ACE inhibitors were also studied in individuals who had experienced heart attacks but were not yet showing symptoms of heart failure.

FutureWise Market Research has published a report that provides an insightful analysis angiotensin converting enzyme (ACE) inhibitors market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, angiotensin converting enzyme (ACE) inhibitors market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Abbott
  • Bausch Health Companies Inc.
  • AbbVie Inc.
  • Pfizer Inc.
  • DAIICHI SANKYO COMPANY, LIMITED
  • Novartis AG
  • Merck KGaA
  • La Jolla Pharmaceutical Company
  • Quantum Genomics
  • AstraZeneca
  • Johnson and Johnson Services, Inc.
  • Eli Lilly and Company
  • Par Pharmaceutical
  • Sanofi
  • Bristol-Myers Squibb Company
  • Sandoz AG
  • Mayo Foundation for Medical Education and Research (MFMER)
  • Bayer AG
  • Takeda Pharmaceutical Company Limited
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in Angiotensin Converting Enzyme (ACE) Inhibitors Market:

  • In May 2021, Novartis made a significant announcement regarding its latest ACE inhibitor medication, Entresto. The FDA granted approval for this drug to treat heart failure, demonstrating its efficacy in reducing hospitalization and mortality risks among heart failure patients.

  • In February 2023, Travere Therapeutics, a US-based biopharmaceutical company, announced FDA approval of FILSPARI (sparsentan), a first-of-its-kind non-immunosuppressive therapy for use in patients with IgA nephropathy (IgAN). These treatments include systemic glucocorticoids, angiotensin-converting enzyme (ACE) inhibitors, and hypertensive medications, including angiotensin receptor blockers.

The increasing prevalence of hypertension disorders is expected to drive the growth of the Angiotensin Converting Enzyme (ACE) Inhibitors Market due to the rising global burden of hypertension, which affects a large population worldwide. As a primary treatment option for hypertension, healthcare professionals widely prescribe ACE inhibitors to manage blood pressure effectively and reduce the risk of cardiovascular events. For instance, in March 2023, according to WHO, a Switzerland-based specialized agency of the United Nations, approximately 1.28 billion adults between the ages of 30 and 79 were affected by hypertension worldwide, with a majority residing in low and middle-income nations. Additionally, the increasing consciousness of the benefits of early diagnosis and treatment, advancements in medical technology, and initiatives promoting preventive healthcare will likely contribute to the growing demand for ACE inhibitors, propelling market expansion during the forecast period. Furthermore, the lack of a favorable reimbursement scenario and limited technology penetration in developing countries is anticipated to hinder the Angiotensin Converting Enzyme (ACE) Inhibitors Market during the forecast period. In these regions, healthcare systems may not adequately cover the costs of ACE inhibitors, potentially limiting patient access to these medications. Additionally, low- and middle-income countries may struggle with inadequate infrastructure, including healthcare facilities and distribution networks, hindering the efficient supply and distribution of ACE inhibitors to patients in need. These factors may impede the market's growth and adoption of ACE inhibitors in regions with limited resources and healthcare infrastructure.

By Drug

  • Lisinopril
  • Ramipril
  • Enalapril
  • Benazepril
  • Fosinopril
  • Captopril
  • Moexipril
  • Others

By Application

  • Heart Failure
  • Hypertension
  • Diabetes
  • Heart Attack
  • Chronic Kidney Disease
  • Others

By Distribution Channel

  • Retail Pharmacy
  • Hospital Pharmacy
  • E-Commerce Websites
  • Online Drug Stores

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Owing to rising heart diseases and obesity in the population, favorable reimbursement policies, and increasing Research & development activities for developing new drugs for treatment. Heart disease is the major cause of mortality in the U.S., closely followed by cancer and chronic respiratory diseases. The well-established healthcare infrastructure and high public awareness regarding the diagnosis, treatment, and management of lifestyle diseases further contribute to the growth of the ACE inhibitors market in the region.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug, By Application, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders

  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study

  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Angiotensin Converting Enzyme (ACE) Inhibitors Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Drug Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Lisinopril
        2. Ramipril
        3. Enalapril
        4. Benazepril
        5. Fosinopril
        6. Captopril
        7. Moexipril
        8. Others

  • 8.   Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Heart Failure
        2. Hypertension
        3. Diabetes
        4. Heart Attack
        5. Chronic Kidney Disease
        6. Others

  • 9.   Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Retail Pharmacy
        2. Hospital Pharmacy
        3. E-Commerce Websites
        4. Online Drug Stores

  • 10.   North America Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Abbott
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Bausch Health Companies Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. AbbVie Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Pfizer Inc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. DAIICHI SANKYO COMPANY, LIMITED
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Novartis AG
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Merck KGaA
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. La Jolla Pharmaceutical Company
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Quantum Genomics
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. AstraZeneca
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Johnson and Johnson Services, Inc.
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Eli Lilly and Company
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Par Pharmaceutical
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Sanofi
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Bristol-Myers Squibb Company
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Sandoz AG
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Mayo Foundation for Medical Education and Research (MFMER)
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Bayer AG
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
        19. Takeda Pharmaceutical Company Limited
         19.1. Company Overview
         19.2. Product Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview
        20. GlaxoSmithKline plc
         20.1. Company Overview
         20.2. Product Portfolio
         20.3. SWOT Analysis
         .20.4. Financial Overview
         20.5. Strategic Overview
        21. Teva Pharmaceutical Industries Ltd.
         21.1. Company Overview
         21.2. Product Portfolio
         21.3. SWOT Analysis
         21.4. Financial Overview
         21.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated
      by administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients